Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2023 Financial Results
Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2023.
- Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2023.
- Consolidated revenues for the third quarter of fiscal 2023 were $7.87 million compared to $7.68 million for the third quarter of fiscal 2022.
- The revenues for the third quarter of fiscal 2023 consisted of $7.86 million in processing and storage fees, $3,000 in product revenue and $4,000 in public banking revenue compared to $7.52 million in processing and storage fees, $21,000 in product revenue and $138,000 in public banking revenue for the third quarter of fiscal 2022.
- During the three months ended August 31, 2023, revenue increased 2%, cost of sales decreased 8% and selling, general and administration expenses increased 6%.